A World’s First Multi-Layered Mechanism of Action
Unlike current antibiotics, which are typically naturally occurring in certain fungi and soil bacteria, Recce’s anti-infectives are wholly synthetic and based on a patented polymeric structure and have been designed to overcome resistance. Traditional antibiotics inhibit a single target such as bacterial gyrase enzymes, cell wall biosynthetic enzymes, or enzymes required for DNA replication during bacterial cell division. They operate on a ‘lock and key’ mechanism and therefore only bind to a few active sites on the bacterial target. However, if a mutation is introduced into the target site, then the antibiotic will cease to be effective.
The Science
Behind R327
STAGE 1
R327 permeabilizes cell membrane and enters the cell
STAGE 2
R327 interrupts bacterial cellularenergetics via ATP synthesis
STAGE 3
Cellular division & non-dividing cell functions are disrupted
STAGE 4
R327 is rapidly and irreversibly bactericidal
A Multi-Layered Mechanism of Action
R327 activity against Escherichia coli
R327 activity against Staphylococcus aureus
Without R327
R327 (3,000 ppm)
- R327 at 3,000 ppm shown to be highly effective against E. coli - not allowing it to divide and grow.
- Healthy eukaryotic cells remain unaffected and continue to grow.
- R327 rapidly and irreversibly shuts down the ATP in E. coli.
Without R327
R327 (2,300 ppm)
- R327 at 2,300 ppm shown to be highly effective against S. aureus - not allowing it to divide and grow.
- Healthy eukaryotic cells remain unaffected and continue to grow.
- R327 rapidly and irreversibly shuts down the ATP in S. aureus.
R327 works to kill bacteria ‘unlike any antibiotic ever seen’ with multiple mechanisms of action. R327 is rapidly and irreversibly bactericidal against Gram-negative E. coli bacteria in both active and stationary phase cell with the potential to outperform the best in class commercial antibiotics.
A Multi-Layered Mechanism of Action
R327 activity against Escherichia coli
Without R327
R327 (3,000 ppm)
- R327 at 3,000 ppm shown to be highly effective against E. coli without affecting growing, healthy eukaryotic cells.
- R327 rapidly and irreversibly shuts down the ATP in E. coli, not allowing it to divide and grow.
R327 activity against Staphylococcus aureus
Without R327
R327 (2,300 ppm)
- R327 at 2,300 ppm shows to be highly effective against S. aureus without affecting growing, healthy eukaryotic cells.
- R327 rapidly and irreversibly shuts down the ATP in S. aureus, not allowing it to divide and grow.
R327 works to kill bacteria ‘unlike any antibiotic ever seen’ with multiple mechanisms of action. R327 is rapidly and irreversibly bactericidal against Gram-negative E.coli bacteria in both active and stationary phase cell with the potential to outperform the best in class commerical antibiotics.
More MoA Info
RECCE® 327 may be administered for intravenous, topical, nasal, oral and inhaled use. RECCE® 327’s universal mechanism of action has a patented ability to continuously kill bacteria without tendency for the emergence of resistance, even with repeated use, indicating a unique ability to combat antibiotic-resistant superbugs.
R327 rapidly and irreversibly shuts down cellular energetics (adenosine triphosphate (ATP) production) – primary MoA
R327 affects the assembly of bacterial cell division complex, components that require cellular energy to remain assembled, confirming its ability to disrupt cellular bioenergetics
R327 results in the decreased formation of the bacterial cell division complex into ring-like structures (Z-rings) in a concentration dependent manner
R327 permeabilises the cell membrane/alters the integrity of the outer membrane of Escherichia coli (E. coli) cells – intended activity without toxicity
R327 demonstrate a faster kill rate than existing antibiotics (bacterial bursting due to their uniquely high internal pressures)
R327 rapidly and irreversibly bactericidal to slow-growing, quiescent or stationary phase E. coli cells in addition to actively dividing E. coli cells
Within a minute, the highest concentration of R327 used, 5x minimum inhibitory concentration (MIC), was observed to reduce viable cell counts reported as cell forming units per millilitre of culture (CFU/ml) 100-fold (>1x10⁷ to 1x10⁵ at timepoint 0)
Current antibiotics rarely retain bactericidal activities against nondividing or stationary phase bacterial cells; however, R327 showed remarkable activity against slow-growing bacteria thereby indicating potential antibacterial activity in biofilms
